TIL Key Statistics, Chart & Performance
The current stock price of TIL is 7.13 USD. In the past month the price decreased by -37.4%. In the past year, price decreased by -64.08%.
TIL Latest News, Press Relases and Analysis
TIL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About TIL
Company Profile
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2021-03-19. The firm seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.
Company Info
INSTIL BIO INC
3963 Maple Avenue, Suite 350
Dallas TEXAS 75219 US
CEO: Bronson Crouch
Employees: 14
Phone: 19724993350
INSTIL BIO INC / TIL FAQ
What does TIL do?
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2021-03-19. The firm seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.
What is the current price of TIL stock?
The current stock price of TIL is 7.13 USD. The price decreased by -3.52% in the last trading session.
What is the dividend status of INSTIL BIO INC?
TIL does not pay a dividend.
What is the ChartMill rating of INSTIL BIO INC stock?
TIL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is TIL stock listed?
TIL stock is listed on the Nasdaq exchange.
Can you provide the upcoming earnings date for INSTIL BIO INC?
INSTIL BIO INC (TIL) will report earnings on 2026-03-02, after the market close.
TIL Technical Analysis
TIL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TIL. TIL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TIL Financial Highlights
Over the last trailing twelve months TIL reported a non-GAAP Earnings per Share(EPS) of -11.39. The EPS increased by 1.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.45% | ||
| ROE | -62.34% | ||
| Debt/Equity | 0.7 |
TIL Forecast & Estimates
8 analysts have analysed TIL and the average price target is 97.67 USD. This implies a price increase of 1269.78% is expected in the next year compared to the current price of 7.13.